Eli Lilly (LLY) said Tuesday that it has launched 7.5 milligram and 10 milligram single-dose vials of Zepbound or Tirzepatide, priced at $499 per month through its self-pay Journey program.
The company also said it has lowered the prices of its 2.5 milligram and 5 milligram vials to $349 and $499 per month, respectively.
These new options are only available through "LillyDirect," Eli Lilly said, a system for direct pricing that removes third-party supply chain involvement.
Zepbound is also available in prefilled pens, with weekly maintenance doses of 5 milligrams, 10 milligrams, or 15 milligrams, the company said.
The company's shares were up 1.8% in recent Tuesday premarket activity.
Price: 896.51, Change: +15.11, Percent Change: +1.7
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。